8 January 2018 in ACS Chemical Neuroscience
26 February 2021 in RSC Advances
Tauopathies are a group of disorders in which the deposition of abnormally folded tau protein accompanies neurodegeneration. The development of methods for detection and classification of pathological changes in protein conformation are desirable for understanding the factors that influence the structural polymorphism of aggregates in tauopathies. We have previously demonstrated the utility of Raman spectroscopy for the characterization and discrimination of different protein aggregates, including tau, based on their unique conformational signatures. Building on this, in the present study, we assess the utility of Raman spectroscopy for characterizing and distinguishing different conformers of the same protein which in the case of tau are unique tau strains generated in vitro. We now investigate the impact of aggregation environment, cofactors, post-translational modification and primary sequence on the Raman fingerprint of tau fibrils. Using quantitative conformational fingerprinting and multivariate statistical analysis, we found that the aggregation of tau in different buffer conditions resulted in the formation of distinct fibril strains. Unique spectral markers were identified for tau fibrils generated using heparin or RNA cofactors, as well as for phosphorylated tau. We also determined that the primary sequence of the tau monomer influenced the conformational signature of the resulting tau fibril, including 2N4R, 0N3R, K18 and P301S tau variants. These results highlight the conformational polymorphism of tau fibrils, which is reflected in the wide range of associated neurological disorders. Furthermore, the analyses presented in this study provide a benchmark for the Raman spectroscopic characterization of tau strains, which may shed light on how the aggregation environment, cofactors and post-translational modifications influence tau conformation in vivo in future studies.
6 September 2019 in ACS Chemical Neuroscience
3 October 2024 in Alzheimer's & Dementia
INTRODUCTION: As aggregation underpins Tau toxicity, aggregation inhibitor peptides may have disease‐modifying potential. They are therefore currently being designed and target either the 306VQIVYK311 aggregation‐promoting hotspot found in all Tau isoforms or the 275VQIINK280 aggregation‐promoting hotspot found in 4R isoforms. However, for any Tau aggregation inhibitor to potentially be clinically relevant for other tauopathies, it should target both hotspots to suppress aggregation of Tau isoforms, be stable, cross the blood‐brain barrier, and rescue aggregation‐dependent Tau phenotypes in vivo.METHODS: We developed a retro‐inverso, stable D‐amino peptide, RI‐AG03 [Ac‐rrrrrrrrGpkyk(ac)iqvGr‐NH2], based on the 306VQIVYK311 hotspots which exhibit these disease‐relevant attributes.RESULTS: Unlike other aggregation inhibitors, RI‐AG03 effectively suppresses aggregation of multiple Tau species containing both hotspots in vitro and in vivo, is non‐toxic, and suppresses aggregation‐dependent neurodegenerative and behavioral phenotypes.DISCUSSION: RI‐AG03 therefore meets many clinically relevant requirements for an anti‐aggregation Tau therapeutic and should be explored further for its disease‐modifying potential for Tauopathies.Highlights: Our manuscript describes the development of a novel peptide inhibitor of Tau aggregation, a retro‐inverso, stable D‐amino peptide called RI‐AG03 that displays many clinically relevant attributes. We show its efficacy in preventing Tau aggregation in both in vitro and in vivo experimental models while being non‐toxic to cells. RI‐AG03 also rescues a biosensor cell line that stably expresses Tau repeat domains with the P301S mutation fused to Cer/Clo and rescues aggregation‐dependent phenotypes in vivo, suppressing neurodegeneration and extending lifespan. Collectively our data describe several properties and attributes of RI‐AG03 that make it a promising disease‐modifying candidate to explore for reducing pathogenic Tau aggregation in Tauopathies such as Alzheimer's disease. Given the real interest in reducing Tau aggregation and the potential clinical benefit of using such agents in clinical practice, RI‐AG03 should be investigated further for the treatment of Tauopathies after validation in mammalian models. Tau aggregation inhibitors are the obvious first choice as Tau‐based therapies as much of Tau‐mediated toxicity is aggregation dependent. Indeed, there are many research efforts focusing on this therapeutic strategy with aggregation inhibitors being designed against one of the two aggregation‐promoting hotspots of the Tau protein. To our knowledge, RI‐AG03 is the only peptide aggregation inhibitor that inhibits aggregation of Tau by targeting both aggregation‐promoting hotspot motifs simultaneously. As such, we believe that our study will have a significant impact on drug discovery efforts in this arena.
28 July 2020 in Biomedical Optics Express
Specific proteins and their aggregates form toxic amyloid plaques and neurofibrillary tangles in the brains of people suffering from neurodegenerative diseases such as Alzheimer’s and Parkinson’s. It is important to study these conformational changes to identify and differentiate these diseases at an early stage so that timely medication is provided to patients. Mid-infrared spectroscopy can be used to monitor these changes by studying the line-shapes and the relative absorbances of amide bands present in proteins. This work focusses on the spectroscopy of the protein, Bovine Serum Albumin as an exemplar, and its aggregates using germanium on silicon waveguides in the 1900–1000 cm−1 (5.3–10.0 µm) spectral region.
8 February 2022 in bioRxiv
Current methods for diagnosing acute and complex infections mostly rely on culture-based methods and, for biofilms, fluorescence in-situ hybridization. These techniques are labor-intensive and can take 2-4 days to return a test result, especially considering an extra culturing step required for the antibiotic susceptibility testing (AST). This places a significant burden on healthcare providers, delaying treatment and leading to adverse patient outcomes. Here, we report the complementary use of our newly developed multi-excitation Raman spectroscopy (ME-RS) method with whole-genome sequencing (WGS). Four WHO priority pathogens are AST phenotyped and their antimicrobial resistance (AMR) profile determined by WGS. On application of ME-RS method we find high correlation with the WGS characterization. Highly accurate classification based on the species (98.93%), wild-type/non-wild type (99.45%), and presence or absence of thick peptidoglycan layers in cell walls (100%), as well as at the individual strain level (99.29%). These results clearly demonstrate the potential of ME-RS as a rapid and first-stage tool for species, resistance and strain-level classification which can be followed up by WGS for confirmation. Such a workflow can facilitate efficient antimicrobial stewardship to handle and prevent the spread of AMR.